تقرير
أعرض في EDS

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

التفاصيل البيبلوغرافية
العنوان: Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
المؤلفون: AstraZeneca
المصدر: BrUOG 413: A Phase II Study of Adjuvant Trastuzumab Deruxtecan (Enhertu) + Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2-Positive Cancers of the Esophagus and Gastroesophageal Junction
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05480384Test
قاعدة البيانات: ClinicalTrials.gov
الوصف
الوصف غير متاح.